Vanda And The $1 Billion Question With Fanapt

Will Vanda's Fanapt sales be as huge as some analysts suggest?

Vanda And The $1 Billion Question With Fanapt Vanda And The $1 Billion Question With Fanapt

Biotechs Selling For Less Than Net Cash

It is possible to buy shares of a drug developer for less than the value of the cash on its balance sheet

Biotechs Selling For Less Than Net Cash Biotechs Selling For Less Than Net Cash

A Dendreon Valuation Model

A model of what shares of Dendreon (Nasdaq: DNDN) might be worth after the success of Provenge in IMPACT

A Dendreon Valuation Model A Dendreon Valuation Model

21st Century Biotech IPO Performance

Lets look at the performance of all the (bio)pharmas that have IPOed in the 21st century

21st Century Biotech IPO Performance 21st Century Biotech IPO Performance
« 1 2 3

Daily Stock Price Δ

NASDAQ2236.92  chart +0.03%
S&P 5001105.37  chart +0.11%
AMGN53.84  chart +0.09%
GENZ70.61  chart -0.03%
GILD34.28  chart +0.68%
BIIB57.21  chart +0.35%
PFE16.87  chart +0.60%
MRK36.18  chart +0.28%
GSK39.37  chart -0.33%
NVS53.69  chart -0.11%
RHHBY.PK35.08  chart -0.85%
BAY.DE47.71  chart -0.92%
^BTK1128.84  chart +0.32%
^NBI866.93  chart +0.27%
WYE50.39  chart +0.00%
VPHM12.97  chart -0.84%
FACT0.00  chart -0.84%
ELN4.66  chart +0.00%
09-10-10 09:48

Latest Articles

Useful Sites